Treatment of skin, XXXX with @entity5505 .

@entity1 @entity5503 @entity2890 @entity5414 @entity4034 @entity2688 @entity2585 @entity281 @entity4967 @entity79 @entity272 @entity1793 @entity5505
The collective experience with @entity5505 in the treatment of skin, soft tissue, bone, and joint @entity281 is presented. @entity1 were treated with dosages ranging between 25 and 150 mg/kg per day for between five and 42 days. A total of 570 @entity1 with skin and @entity272 were treated with @entity5505 . Comparative studies, using either @entity5503 or @entity2890 plus @entity4967 as control drugs, included 239 @entity1 . There were 600 evaluable @entity1 in five categories of skin or skin structure infection: 252 @entity1 had @entity2688 , 107 had wound @entity281 , 103 had abscesses, 90 had skin ulcers, and 48 had other miscellaneous @entity281 . Bacteriologic etiologies were gram-negative rods in 303 episodes, gram-positive cocci in 241, anaerobes in 14 episodes, and miscellaneous other organisms in 48 episodes. Overall bacteriologic efficacy was 90 percent in @entity5505 -treated @entity281 and 76 percent in control-treated @entity281 . The clinical efficacy of @entity5505 against @entity281 caused by the gram-positive cocci, particularly Staphylococcus species, was surprisingly good (85 percent) and similar to the efficacy achieved in the @entity5503 -treated @entity1 (85 percent). The overall clinical efficacy for @entity5505 was 93 percent. One hundred thirty-four @entity1 with bone or joint @entity281 received @entity5505 . The dosages were similar, but the duration of treatment was the longest in this group. @entity5505 treatment was compared with standard dosages of @entity2890 and @entity4967 in 11 @entity1 . @entity4034 was cured in 58 of the 101 @entity1 who received @entity5505 . In five @entity1 , @entity4034 failed to respond: in two, a resistant Pseudomonas strain emerged; the other three failures were due to persistent bone sequestra. Thirty-eight @entity1 showed improvement. Of those in the @entity2890 and @entity4967 group, nine of 10 evaluable @entity1 (90 percent) showed either cure or improvement. The one failure was due to a persistent sequestrum. Thirteen @entity1 with @entity5414 and seven with @entity2585 were also treated with @entity5505 ; the overall cure rate was 75 percent. Adverse reactions to @entity5505 were severe, and the drug was discontinued in 13 of 570 (2.3 percent) @entity1 with skin or @entity272 and in five of 134 (3.7 percent) @entity1 with @entity79 . These data suggest that @entity5505 is effective as monotherapy in the treatment of skin, @entity79 , and that it may be more efficacious against @entity1793 than predicted from in vitro data.
